6533b820fe1ef96bd1279ac5

RESEARCH PRODUCT

Chitosan-coated mesoporous MIL-100(Fe) nanoparticles as improved bio-compatible oral nanocarriers

subject

description

Nanometric biocompatible Metal-Organic Frameworks (nanoMOFs) are promising candidates for drug delivery. Up to now, most studies have targeted the intravenous route, related to pain and severe complications; whereas nanoMOFs for oral administration, a commonly used non-invasive and simpler route, remains however unexplored. We propose here the biofriendly preparation of a suitable oral nanocarrier based on the benchmarked biocompatible mesoporous iron(III) trimesate nanoparticles coated with the bioadhesive polysaccharide chitosan (CS). This method does not hamper the textural/structural properties and the sorption/release abilities of the nanoMOFs upon surface engineering. The interaction between the CS and the nanoparticles has been characterized through a combination of high resolution soft X-ray absorption and computing simulation, while the positive impact of the coating on the colloidal and chemical stability under oral simulated conditions is here demonstrated. Finally, the intestinal barrier bypass capability and biocompatibility of CS-coated nanoMOF have been assessed in vitro, leading to an increased intestinal permeability with respect to the non-coated material, maintaining an optimal biocompatibility. In conclusion, the preservation of the interesting physicochemical features of the CS-coated nanoMOF and their adapted colloidal stability and progressive biodegradation, together with their improved intestinal barrier bypass, make these nanoparticles a promising oral nanocarrier This work was partially supported by the UVSQ and the CNRS, the French ANR through a VirMIL MatePro project and “Investissements d’Avenir” program (Labex NanoSaclay: ANR-10-LBX-0035). PH acknowledges the Spanish Ramon y Cajal Programme (grant agreement no. 2014-16823). M.G.-M. thanks the EU for a Marie Sklodowska-Curie postdoctoral fellowship (H2020-MSCA-IF-658224). We also thanks to the BIOCAPS project (316265, FP7/REGPOT-2012-2013.1) and Xunta de Galicia: Agrupación Estratégica para la Investigación en Biomedicina (INBIOMED) and grupo de potencial de Crecimiento (GPC2013-005) SI